Dianthus Therapeutics, Inc.
DNTH
Ранг среди акций
#3826
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Цена акции
$77.80
Рыночная капитализация
$4.35B
Изменение (1 день)
-1.21%
Изменение (1 год)
122.10%
Страна
US
Торговля Dianthus Therapeutics, Inc. (DNTH)
Категория
Healthcare
История цены акций Dianthus Therapeutics, Inc. (DNTH)
Наивысшая цена закрытия: $80.75 2026-10-01
Наименьшая цена закрытия: $225.69 2018-06-01
Наименьшая цена закрытия: $225.69 2018-06-01
История цены акций Dianthus Therapeutics, Inc. с 2018 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | 74.03% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
